<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375972</url>
  </required_header>
  <id_info>
    <org_study_id>AMC_0803</org_study_id>
    <nct_id>NCT01375972</nct_id>
  </id_info>
  <brief_title>Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma</brief_title>
  <official_title>Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To select a better agent between S-1 or gemcitabine in combination with cisplatin for the
      conventional chemotherapy platform for future development in advanced Biliary Tract
      Adenocarcinoma (BTA), the investigators conduct a randomized phase II trial of S-1 and
      cisplatin (SP) versus gemcitabine and cisplatin (GP) as first line therapy in advanced BTA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>progression-free survival wad defined as the time from the date of enrollment to the date of the first occurrence of objective disease progression or death from any cause, which occur first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Response to chemotherapy will be assessed using RECIST 1.0 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Toxicities associated chemotherapy will be assessed and categorized using NCI CTCAE v3.0. The types of toxicities and the proportions of patients who experience each toxicity will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Overall survival is calculated from the date of enrollment to the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Metastatic Biliary Cancer</condition>
  <arm_group>
    <arm_group_label>SP treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 plus cisplatin combination chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine plus Cisplatin combination chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 plus cisplatin</intervention_name>
    <description>S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks</description>
    <arm_group_label>SP treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus Cisplatin</intervention_name>
    <description>Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks</description>
    <arm_group_label>GP treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically proven biliary adenocarinoma

          2. Age &gt; 18

          3. Evaluable disease

          4. ECOG performance status of 2 or better

          5. No prior exposure to chemotherapy, but adjuvant chemotherapy (or chemoradiotherapy)
             completed 6 moths or more before study enrollment is allowed

          6. Adequate bone marrow function A. WBCs &gt; 4,000/µL, absolute neutrophil count
             [ANC]&gt;1,500/µL B. Hemoglobin &gt;9.0 g/dL C. Platelets &gt; 100,000/µL

          7. Adequate kidney function (creatinine&lt;1.5 mg/dL)

          8. Adequate liver function (bilirubin&lt;1.5 mg/dL [&lt; 2.5 mg/dL for obstructive jaundice
             with adequately decompressed bile duct obstruction], transaminases levels&lt;3 times the
             upper normal limit, and serum albumin of &gt;2.5 mg/dL)

          9. No serious medical or psychological condition that would preclude study treatment

         10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures

        Exclusion Criteria:

          1. Other tumor type than adenocarcinoma

          2. Evidence of GI bleeding or GI obstruction

          3. Presence or history of CNS metastasis

          4. Pregnancy or breastfeeding

          5. Other serious illness or medical conditions

          6. Axial skeletal radiotherapy within 6 months

          7. Neuropathy grade 2 or worse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MJ Kang, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>JLee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>biliary cancer</keyword>
  <keyword>systemic chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

